Yet another attempt at receptor mediated transcytosis across the BBB.  Let's look at this technology:

.

"The scientists assembled the large molecular agents by merging part of a fatty protein called apolipoprotein E (apoE)".

.

The particular receptor that is utilized for apoE transport, is LRP1 (reference the following Plosone Article if you want more particulars on this)

.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0032568

.

Angiochem's EPIC technology is also based on LRP1 and we recently discussed the failure of this in the Geron trials.  Don't forget, that being able to show efficacy in LSD diseases is a very low threshold.  We saw from the Shire Intrathecal study last year, that they had a therapeutic effect on less than 1% and closer to .5%.

.

In a sense, I hope that there will be another BBB transport technology come along that is as successful as TRANSCEND (well maybe not quite as successful), as it would show a renewed interest by pharmas in CNS disease treatment.  There is plenty of room in the BBB transport space for more than 1 player.  In my opinion, it will shine a brighter light on the urgency for pharma to advance their CNS programs.  At the moment, there is skepticism amongst the pharmas in being able to transport biologics across the BBB and failures such as Geron reinforce that idea.  Success is what we need in the BBB transport space and the more the merrier.